EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID)

The article describes the monitoring of severe cryopyrin-associated syndrome (syndrome CINCA/NOMID). The following clinical case indicates successful application of homogeneous antibodies to interleukin 1 - canakinumab - in patient with chronic neurologic dermatic articular syndrome. Fever, rush and...

Full description

Saved in:
Bibliographic Details
Main Authors: T. V. Sleptsova (Author), E. I. Alexeeva (Author), K. V. Savost'yanov (Author), A. A. Pushkov (Author), A. G. Nikitin (Author), T. M. Bzarova (Author), S. I. Valieva (Author), A. N. Fetisova (Author), A. V. Pakhomov (Author), N. V. Zhurkova (Author), R. V. Denisova (Author), K. B. Isaeva (Author), E. G. Chistyakova (Author)
Format: Book
Published: "Paediatrician" Publishers LLC, 2014-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_c4e2f6cb60724f079bcaac6c72e71609
042 |a dc 
100 1 0 |a T. V. Sleptsova  |e author 
700 1 0 |a E. I. Alexeeva  |e author 
700 1 0 |a K. V. Savost'yanov  |e author 
700 1 0 |a A. A. Pushkov  |e author 
700 1 0 |a A. G. Nikitin  |e author 
700 1 0 |a T. M. Bzarova  |e author 
700 1 0 |a S. I. Valieva  |e author 
700 1 0 |a A. N. Fetisova  |e author 
700 1 0 |a A. V. Pakhomov  |e author 
700 1 0 |a N. V. Zhurkova  |e author 
700 1 0 |a R. V. Denisova  |e author 
700 1 0 |a K. B. Isaeva  |e author 
700 1 0 |a E. G. Chistyakova  |e author 
245 0 0 |a EXPERIENCE IN APPLICATION OF CANAKINUMAB IN PATIENTS WITH CRYOPYRIN-ASSOCIATED SYNDROME (SYNDROME CINCA/NOMID) 
260 |b "Paediatrician" Publishers LLC,   |c 2014-05-01T00:00:00Z. 
500 |a 1682-5527 
500 |a 1682-5535 
500 |a 10.15690/vsp.v13i3.1035 
520 |a The article describes the monitoring of severe cryopyrin-associated syndrome (syndrome CINCA/NOMID). The following clinical case indicates successful application of homogeneous antibodies to interleukin 1 - canakinumab - in patient with chronic neurologic dermatic articular syndrome. Fever, rush and pain syndrome completely jugulated, contractures of articulation joints decreased in a week since the beginning of the treatment. In 8 weeks of therapy movements of affected joints almost completely restored, the boy could stay, spell simple words; decreased and normalized laboratory test values of disease activity (erythrocyte sedimentation rate, C-reactive protein). In 12 weeks the child could move with assistance, say simple phrases. The following clinical case shows high efficiency of application of canakinumab in chronic neurologic dermatic articular syndrome treatment and indicates the perspectives of therapeutic use of interleukin 1 blocking agent in patients with early stage of disease before the progress of nonreversible osteohondrous destruction and serious injury of cerebrospinal nervous system. No adverse event were registered on treatment with application of canakinumab.Key words: children, autophologistic syndromes, cryopyrin-associated syndrome, CINCA/NOMID, canakinumab. 
546 |a EN 
546 |a RU 
690 |a children 
690 |a autophologistic syndromes 
690 |a cryopyrin-associated syndrome 
690 |a cinca/nomid 
690 |a canakinumab 
690 |a Pediatrics 
690 |a RJ1-570 
655 7 |a article  |2 local 
786 0 |n Вопросы современной педиатрии, Vol 13, Iss 3, Pp 97-103 (2014) 
787 0 |n https://vsp.spr-journal.ru/jour/article/view/199 
787 0 |n https://doaj.org/toc/1682-5527 
787 0 |n https://doaj.org/toc/1682-5535 
856 4 1 |u https://doaj.org/article/c4e2f6cb60724f079bcaac6c72e71609  |z Connect to this object online.